

Director: Dr MT Rees
Manager: Mrs D Pritchard

Tel: +44 (0) 1443 622185
Fax: +44 (0) 1443 622001
Email: ukneqashandi@wales.nhs.uk

Correspondence to:
UK NEQAS for H&I
Welsh Blood Service
Ely Valley Road
Talbot Green
Pontyclun CF72 9WB

Educational Crossmatching Scheme

Dispatched on the 9th July 2019

Summary of Results

A total of 34 reports were received, but not all labs reported results for all tests.

Consensus HLA Type of whole blood donor sample EDXM 01/2019:

	A*	B*	C*	DRB1*	DRB4*	DRB5*	DQA1*	DQB1*	DPA1*	DPB1*
	03	07	05	09	01	01	01	03	01	02:01
	32	15	07	15	-	-	03	06	-	126
Number of reports	34	34	33	34	23	23	29	34	19	20
% Labs in consensus	100%	100%	100%	100%	100%	100%	100%	100%	100%	65%

EDXM 01 Serum 1/2019 Results

HLA Antibody Detection and Definition

(Based on 75% Consensus)

		HLA Class I	No of labs	% consensus	HLA Class II	No of labs	% consensus
Detection	IgG	Positive	33	100%	Positive	33	100%
	IgM	Negative	3	100%	Not Assessed	2	50%
Definition ¹	Total Number of Specificities Reported (by ≥ 1 lab)	85			46		
	Number of Specificities Absent (reported by < 5% labs)	4			0		
	Number of Specificities Present (reported by ≥ 75% labs)	34			14		
	MFI >10000	A1 A3 A24 A11 A36 A80 B7 B13 B27 B2708 B60 B61 B42 B48 B67 B81	33	76-100%	DR17 DR18 DR11 DR12 DR13 DR14 DR7 DR8 DR52 DQ2	33	97-100%
	MFI 5001 - 9999	A30 A31 A32 A74 B55 B56 B73 B82		97-100%	DR9		100%
MFI 2001 - 5000	A23 A25 A34 A66 A29 A33 B57 B54 B47	79-100%		DR15	97%		
MFI <2000	B58	82%		DR103 DR16	79-85%		

¹ 75% consensus 'present' specificities are displayed within the MFI value range reported by the majority of participants

Director: Dr MT Rees
Manager: Mrs D Pritchard

Tel: +44 (0) 1443 622185
Fax: +44 (0) 1443 622001
Email: ukneqashandi@wales.nhs.uk

Correspondence to:
UK NEQAS for H&I
Welsh Blood Service
Ely Valley Road
Talbot Green
Pontyclun CF72 9WB

Crossmatching
(Based on 75% Consensus)

	CDC						Flow Cytometry	
	PBL		T Cells		B Cells		T Cells	B Cells
	Without DTT	With DTT	Without DTT	With DTT	Without DTT	With DTT		
	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive
Number of reports	5/6	5/6	19/19	18/18	19/20	18/20	26/26	24/24
% Labs in consensus	83%	83%	100%	100%	95%	90%	100%	100%

Interpretation

Identification of Donor Specific Antibodies:

Specificity	No of Participants (n=33)	MFI Range Reported
A3	31 (94%)	6035-22066
A32	33 (100%)	1554-12452
B7	33 (100%)	8792-23377
DR9	31 (94%)	2720-8052
DR15	33 (100%)	535-4150
DQ6	3 (9%)	761-1400
DQ9	7 (21%)	1018-1600

Crossmatch interpretation:

	<i>The most common responses included:</i>
Interpretation based on results	<ul style="list-style-type: none"> Positive CDC crossmatch Positive T and B cell Flow Cytometry crossmatch Multiple Class I and Class II DSAs detected
Assigned risk	<p>Medium n = 2 (6%)</p> <p>High n = 4 (12%)</p> <p>Contraindication n = 28 (82%)</p>
Immunological advice	<ul style="list-style-type: none"> Immunologically high risk – Class I and Class II DSA present Do not proceed to transplant
If advice is not to transplant, recommendations for future transplants	<p>Seek alternative donor: live, deceased or via a kidney sharing scheme.</p> <p>Use desensitisation.</p> <p>Possibly de-list weaker antibodies.</p> <p>Use assays to determine if antibodies are complement fixing.</p>

Director: Dr MT Rees
Manager: Mrs D Pritchard

Tel: +44 (0) 1443 622185
Fax: +44 (0) 1443 622001
Email: ukneqashandi@wales.nhs.uk

Correspondence to:
UK NEQAS for H&I
Welsh Blood Service
Ely Valley Road
Talbot Green
Pontyclun CF72 9WB

EDXM 01 Serum 2/2019 Results

HLA Antibody Detection and Definition
(Based on 75% Consensus)

		HLA Class I	No of labs	% consensus	HLA Class II	No of labs	% consensus
Detection	IgG	Positive	25	74%	Positive	34	100%
	IgM	Not Assessed	3	66.6%	Not Assessed	2	50%
Definition ¹	Total Number of Specificities Reported (by ≥ 1 lab)	86			46		
	Number of Specificities Absent (reported by < 5% labs)	3			0		
	Number of Specificities Present (reported by ≥ 75% labs)	1			4		
	MFI >10000	N/A	33	N/A	DQ7 DQ8 DQ9	33	100%
	MFI 5000 - 9999	N/A		N/A	N/A		N/A
	MFI 3000 - 4999	A66		79%	N/A		N/A
	MFI 1500 -2999	N/A		N/A	DR4		91%

¹ 75% consensus 'present' specificities are displayed within the MFI value range reported by the **majority** of participants

Crossmatching Results
(Based on 75% Consensus)

	CDC						Flow Cytometry	
	PBL		T Cells		B Cells		T Cells	B Cells
	Without DTT	With DTT	Without DTT	With DTT	Without DTT	With DTT		
	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Not Assessed
Number of reports	6/6	6/6	19/19	18/18	18/20	19/20	25/26	11/26
% Labs in consensus	100%	100%	100%	100%	90%	95%	96%	42%

Director: Dr MT Rees
 Manager: Mrs D Pritchard
 Tel: +44 (0) 1443 622185
 Fax: +44 (0) 1443 622001
 Email: ukneqashandi@wales.nhs.uk

Correspondence to:
 UK NEQAS for H&I
 Welsh Blood Service
 Ely Valley Road
 Talbot Green
 Pontyclun CF72 9WB

Interpretation

Identification of Donor Specific Antibodies:

Specificity	No of Participants (n=33)	MFI Range Reported
A3	1 (3%)	<1000
A66	1 (3%)	2437
B7	5 (15%)	645-1411
DQ7	3 (9%)	12965-17739
DQ8	3 (9%)	6929-14627
DQ9	33 (97%)	6088-21575

Crossmatch interpretation:

	<i>The most common responses included:</i>								
Interpretation based on results	<ul style="list-style-type: none"> Negative CDC B crossmatch Positive B cell Flow Cytometry crossmatch DQ9 DSA 								
Assigned risk	<table> <tr> <td>Low</td> <td>n = 3 (9.1%)</td> </tr> <tr> <td>Medium</td> <td>n = 10 (30.3%)</td> </tr> <tr> <td>High</td> <td>n = 10 (30.3%)</td> </tr> <tr> <td>Contraindication</td> <td>n = 10 (30.3%)</td> </tr> </table>	Low	n = 3 (9.1%)	Medium	n = 10 (30.3%)	High	n = 10 (30.3%)	Contraindication	n = 10 (30.3%)
Low	n = 3 (9.1%)								
Medium	n = 10 (30.3%)								
High	n = 10 (30.3%)								
Contraindication	n = 10 (30.3%)								
Immunological advice	<ul style="list-style-type: none"> Perform antibody removal prior to transplant Do not proceed to transplant Regular post-transplant monitoring with increased immunosuppression 								
If advice is not to transplant, recommendations for future transplants	<p>Seek alternative donor: live, deceased or via a kidney sharing scheme.</p> <p>HLAi use appropriate desensitisation.</p> <p>Use assays to determine if antibodies are complement fixing.</p>								

Director: Dr MT Rees
Manager: Mrs D Pritchard

Tel: +44 (0) 1443 622185
Fax: +44 (0) 1443 622001
Email: ukneqashandi@wales.nhs.uk

Correspondence to:
UK NEQAS for H&I
Welsh Blood Service
Ely Valley Road
Talbot Green
Pontyclun CF72 9WB

EDXM 01 Serum 3/2019 Results

HLA Antibody Detection and Definition
(Based on 75% Consensus)

		HLA Class I	No of labs	% consensus	HLA Class II	No of labs	% consensus
Detection	IgG	Negative	33	100%	Negative	33	100%
	IgM	Negative	3	100%	Negative	2	100%
Definition ¹	Total Number of Specificities Reported (by ≥ 1 lab)	84			44		
	Number of Specificities Absent (reported by < 5% labs)	5			2		
	Number of Specificities Present (reported by ≥ 75% labs)	0			0		
	MFI >10000	N/A	33	N/A	N/A	33	N/A
	MFI 5001 - 9999	N/A		N/A	N/A		N/A
	MFI 2001-5000	N/A		N/A	N/A		N/A
	MFI <2000	N/A		N/A	N/A		N/A

¹ 75% consensus 'present' specificities are displayed within the MFI value range reported by the **majority** of participants

Crossmatching
(Based on 75% Consensus)

	CDC						Flow Cytometry	
	PBL		T Cells		B Cells		T Cells	B Cells
	Without DTT	With DTT	Without DTT	With DTT	Without DTT	With DTT		
	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative

Number of reports	6/6	6/6	19/19	18/18	20/20	20/20	25/26	23/24
% Labs in consensus	100%	100%	100%	100%	100%	100%	96%	96%

Director: Dr MT Rees
 Manager: Mrs D Pritchard
 Tel: +44 (0) 1443 622185
 Fax: +44 (0) 1443 622001
 Email: ukneqashandi@wales.nhs.uk

Correspondence to:
 UK NEQAS for H&I
 Welsh Blood Service
 Ely Valley Road
 Talbot Green
 Pontyclun CF72 9WB

Interpretation

No Donor Specific Antibodies detected.

Crossmatch interpretation:

	<i>The most common responses included:</i>
Interpretation based on results	<ul style="list-style-type: none"> Negative CDC crossmatch Negative Flow Cytometry crossmatch No DSAs detected Suitable for transplant
Assigned risk	Low n = 30 (100%)
Immunological advice	<ul style="list-style-type: none"> Low/standard risk transplant Standard immunosuppressive treatment No additional interventions or monitoring required Post-transplant monitoring
If advice is not to transplant, recommendations for future transplants	N/A – proceed to transplant